Hannmi Pharmaceutical's Poziotinib is expected to be designated as BTD
Hannmi Pharmaceutical's Poziotinib is expected to be designated as BTD
  • Kim Min-jee
  • 승인 2018.11.09 13:05
  • 댓글 0
이 기사를 공유합니다

A procedure has begun to designate FDA's Breakthrough Therapy Designation (BTD) for the new anti-cancer drug Poziotinib, developed by Hanmi Pharmaceutical, within this year.

According to a third quarter data released by Spectrum, a partner of Hanmi Pharmaceutical, on October 8 (local time), it has applied to U.S. FDA's BTD. Spectrum said Poziotinib is expected to be designated within this year as an BTD. 

The FDA's BTD system first reviews new drug candidates for treatment of life-threatening diseases and approves the clinical results for two phases of the year.

Hannmi Pharmaceutical is currently undergoing a variety of global clinicians to confirm the potential of targeted and primary treatments for EGFR and HER2 20-variable cell lung cancer patients.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • 2-D 678, National Assembly-daero, 36-gil, Yeongdeungpo-gu, Seoul, Korea (Postal code: 07257)
  • URL: www.koreaittimes.com | Editorial Div: 82-2-578- 0434 / 82-10-2442-9446 | North America Dept: 070-7008-0005 | Email: info@koreaittimes.com
  • Publisher and Editor in Chief: Monica Younsoo Chung | Chief Editorial Writer: Hyoung Joong Kim | Editor: Yeon Jin Jung
  • Juvenile Protection Manager: Choul Woong Yeon
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트